Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
12 April 2023 - 9:00PM
Chiesi Farmaceutici S.p.A. Completes
Acquisition of Amryt
Pharma Plc
- Acquisition positions Chiesi to
expand patient access to approved treatments and advance efforts to
develop new treatments for people living with rare diseases.
Parma Italy, Dublin Ireland and Boston
MA, April 12,
2023 – Chiesi Farmaceutici S.p.A. (“Chiesi”), an
international, research-focused biopharmaceuticals and healthcare
group, today announced the completion of the acquisition of Amryt
Pharma Plc (“Amryt”) (Nasdaq: AMYT), a global, commercial-stage
biopharmaceutical company dedicated to acquiring, developing, and
commercializing novel treatments for rare diseases.
“We are excited to add the Amryt family to our
company in this acquisition that demonstrates our commitment to
rare diseases and aligns with our growth strategy through
partnerships beyond internal research and development,” said
Giacomo Chiesi, head of Chiesi Global Rare
Diseases. “Amryt has unique and clinically differentiated
products and additional promising drugs in its pipeline, and, as a
benefit corporation certified B Corp, Chiesi has a patient-centric
and sustainable model in place to make these treatments available
to even more patients who need them. As of today, we are officially
joining our forces to bring hope to people in need and look forward
to this new chapter in our collective journey.”
“This acquisition reflects Chiesi Group’s
commitment towards patients. Chiesi strives to create a world where
it is common to have a therapy for all diseases and acts as a force
for good for society and the planet,” said
Giuseppe Accogli, CEO
of Chiesi Group “Amryt
Pharma’s team has delivered innovative treatments to rare disease
patients with high unmet medical needs. By joining forces and
expertise we will be able to grow our capabilities and further
strengthen our position to provide a positive impact on patients
living with rare diseases.”
About Chiesi Global Rare
DiseasesChiesi Global Rare Diseases is a business unit of
the Chiesi Group established to deliver innovative therapies and
solutions for people affected by rare diseases. As a family
business, Chiesi Group strives to create a world where it is common
to have a therapy for all diseases and acts as a force for good,
for society and the planet. The goal of the Global Rare Diseases
unit is to ensure equal access so as many people as possible can
experience their most fulfilling life. The unit collaborates with
the rare disease community around the globe to bring voice to
underserved people in the health care system. For more information
visit www.chiesirarediseases.com.
About Chiesi GroupChiesi is an
international, research-focused biopharmaceuticals group that
develops and markets innovative therapeutic solutions in
respiratory health, rare diseases, and specialty care. The
company’s mission is to improve people’s quality of life and act
responsibly towards both the community and the environment. By
changing its legal status to a Benefit Corporation in Italy, the
US, and France, Chiesi’s commitment to create shared value for
society as a whole is legally binding and central to company-wide
decision-making. As a certified B Corp since 2019, we’re part of a
global community of businesses that meet high standards of social
and environmental impact. The company aims to reach Net-Zero
greenhouse gases (GHG) emissions by 2035. With over 85 years of
experience, Chiesi is headquartered in Parma (Italy), operates in
31 countries, and counts more than 6,500 employees. The Group’s
research and development centre in Parma works alongside 6 other
important R&D hubs in France, the US, Canada, China, the UK,
and Sweden.
For further information please visit
www.chiesi.com
About
AmrytAmryt is a global commercial-stage
biopharmaceutical company focused on acquiring, developing and
commercializing innovative treatments to help improve the lives of
patients with rare and orphan diseases. Amryt comprises a strong
and growing portfolio of commercial and development assets. For
more information on Amryt, including products, please visit
www.amrytpharma.com.
Media Contact
Chiara TravaginRare Communication
ManagerMob. +39 348 8818985c.travagin@chiesi.com
Alessio PappagalloPress Office
ManagerMob: +39 339 5897483a.pappagallo@chiesi.com
Jenna UrbanBerry & Company Public
Relations1-212-253-8881jurban@berrypr.com
Amryt Pharma (NASDAQ:AMYT)
Historical Stock Chart
From Jan 2025 to Feb 2025
Amryt Pharma (NASDAQ:AMYT)
Historical Stock Chart
From Feb 2024 to Feb 2025